NCT03821233: A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers

NCT03821233
Breast Cancer Type: HER2++
Hormone Mutations: ER++, PR+
Other Mutations: HER2+-low
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 1
Drug Category: Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with known leptomeningeal disease (LMD); Untreated, unstable, symptomatic CNS metastases that require treatment- see trial for details
https://ClinicalTrials.gov/show/NCT03821233

Comments are closed.

Up ↑